Vitro Biopharma, Inc

About Us

Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB: VODG; http://www.vitrobiopharma.com), owns US patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. Vitro also owns a pending international patent for generation of pluripotent stem cells. Vitro’s mission is “Harnessing the Power of Cells™” for the advancement of regenerative medicine to its full potential. Vitro operates within a modern biotechnology manufacturing, R&D and corporate facility in Golden, Colorado. Vitro manufactures and sells “Tools for Stem Cell and Drug Development™”, including human mesenchymal stem cells and derivatives, MSC-Gro™ optimized media for stem cell self-renewal and lineage-specific differentiation. Vitro recently formed a strategic alliance with HemoGenix®, Inc. to jointly manufacture and distribute LUMENESC™ and LumiSTEM™ quantitative assays for determination of stem cell quality, potency and response to toxic agents.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Vitro Announces Open Letter to Its Shareholders: 2012 Results Drive Strong Performance in 2013

Tue, Dec 11, 2012 14:30 CET

Golden, Colorado—December 11, 2012—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced the following open letter to its shareholders: Dear Fellow Shareholders: I am pleased to report our progress during 2012 including significant advances in our business focused on the development, manufacture and commercial distribution of essential tools to support adult stem cell research and clinical development. The highlights of our achievements in 2012 include: · A new and improved website featuring E-commerce of our products, expanded technical and investor relations

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Vitro Announces Open Letter to Its Shareholders: 2012 Results Drive Strong Performance in 2013

Media